Pular para o conteúdo principal
Ranking Invest

THTX - Theratechnologies Inc.

Segmento: HealthcareTheratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Análise Ranking Invest

Valuation estimado
-$ 123.02 Mi
Último Balanço Atualizado: 2T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 27.92 Mi

Dívida Líquida

$ 34.16 Mi

L4T

-$ 9.16 Mi

MM4T

-10.62%

Indicadores Básicos

ROE

32.79%

Índices de Previsibilidade

Receita Líquida

D0.09

Lucro

E1.69

Margem

F3.95

Índices de Tendência

Receita Líquida

C3.49

Lucro

B7.61

Margem

B7.84

Índices de Endividamento

DIV/PAT

-1.22

DIV/L4T

-3.73

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.